Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease
Portfolio Pulse from
Genentech's Phase IIb study of prasinezumab in early-stage Parkinson's disease did not meet its primary endpoint but showed potential benefits. The study involved 586 participants over 18 months.
December 19, 2024 | 6:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Genentech's Phase IIb study of prasinezumab did not meet its primary endpoint, but showed potential benefits in early-stage Parkinson's disease. This could impact investor sentiment.
The study's failure to meet the primary endpoint may negatively impact investor sentiment. However, the potential benefits observed could offset this, leading to a neutral short-term impact on RHHBY's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80